913 related articles for article (PubMed ID: 6383322)
1. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
2. Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes.
Schorlemmer HU; Bosslet K; Sedlacek HH
Cancer Res; 1983 Sep; 43(9):4148-53. PubMed ID: 6871856
[TBL] [Abstract][Full Text] [Related]
3. Acceleration of age-associated immune decline and mortality by early repeated administration of bestatin to C57BL/6 mice.
Bruley-Rosset M; Payelle B; Rappaport H
J Biol Response Mod; 1986 Apr; 5(2):176-90. PubMed ID: 3488372
[TBL] [Abstract][Full Text] [Related]
4. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
5. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
Colotta F; Peri G; Villa A; Mantovani A
J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory and therapeutic properties of bestatin in mice.
Talmadge JE; Lenz BF; Pennington R; Long C; Phillips H; Schneider M; Tribble H
Cancer Res; 1986 Sep; 46(9):4505-10. PubMed ID: 2942238
[TBL] [Abstract][Full Text] [Related]
7. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
Beland FA
Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulation by the new synthetic thiazole derivative tiprotimod. 2nd communication: immunopharmacological activity.
Schorlemmer HU; Dickneite G; Blumbach J; Dürckheimer W; Sedlacek HH
Arzneimittelforschung; 1989 Sep; 39(9):1085-9. PubMed ID: 2590257
[TBL] [Abstract][Full Text] [Related]
9. Experimental immunological screening tests on pidotimod.
Coppi G; Manzardo S
Arzneimittelforschung; 1994 Dec; 44(12A):1411-6. PubMed ID: 7857333
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction. Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations.
Ghayur T; Seemayer TA; Lapp WS
Transplantation; 1987 Aug; 44(2):254-60. PubMed ID: 3498241
[TBL] [Abstract][Full Text] [Related]
11. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
12. Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies.
Schorlemmer HU; Bosslet K; Kern HF; Sedlacek HH
Behring Inst Mitt; 1988 Apr; (82):240-64. PubMed ID: 3408453
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
14. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
15. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
Tsujino M
Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
[TBL] [Abstract][Full Text] [Related]
16. Restoration of impaired immune functions of aged animals by chronic bestatin treatment.
Bruley-Rosset M; Florentin I; Kiger N; Schulz J; Mathé G
Immunology; 1979 Sep; 38(1):75-83. PubMed ID: 159863
[TBL] [Abstract][Full Text] [Related]
17. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
18. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
19. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
20. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
Thiele DL; Lipsky PE
J Immunol; 1986 Feb; 136(3):1038-48. PubMed ID: 2934477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
